The ANKHD1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HeLa cells, carrying targeted disruptions in the ANKHD1 gene. This heterogeneous pool contains a mixture of cells with diverse loss-of-function mutations, providing a versatile model for investigating ANKHD1 scaffold functions without clonal selection artifacts. Utilizing CRISPR/Cas9-mediated gene editing, this product offers a reliable tool for dissecting the scaffold protein’s contributions to JAK-STAT signaling and oncogenic processes.
The host cell background comprises HeLa cells, an immortalized epithelial cell line originally derived from an HPV18-positive cervical adenocarcinoma. HeLa cells are widely used in biomedical research for their stable karyotype, robust growth, and well-characterized signaling pathways. Their cervical cancer origin and HPV positivity make them particularly relevant for studying oncogenic signaling, while offering a well-established system to examine ANKHD1??s scaffolding role in non-hematopoietic cells.
ANKHD1 functions as a scaffold protein that binds JAK2 and STAT5, facilitating cytokine-induced JAK-STAT pathway activation. In response to upstream ligands IL-3, EPO, and G-CSF, ANKHD1 promotes JAK2-STAT5 complex formation, enhancing STAT5 phosphorylation and transcriptional activity. Key downstream targets include the anti-apoptotic factor BCL2 and the cell cycle regulator CCND1, along with other STAT5 target genes. This scaffold-mediated amplification drives pro-survival and proliferative signals, and its dysregulation contributes to leukemogenesis.
Disruption of ANKHD1 in HeLa cells offers a powerful system to investigate JAK-STAT pathway dynamics in an epithelial cancer model. While ANKHD1 significance is pronounced in leukemia, the JAK2/STAT5 axis is conserved, and its scaffolding function influences cytokine sensitivity, gene expression, and cell fate decisions broadly. This model enables dissection of ANKHD1-dependent and independent signaling events, revealing its specific contributions to proliferation and apoptosis control. It is particularly useful for studying pathway plasticity and the emergence of resistance mechanisms.
This polyclonal knockout pool is suited for a wide range of assays, including Western blotting to monitor STAT5 activation, co-immunoprecipitation to assess JAK2-STAT5 complex integrity, and STAT5 luciferase reporter assays to quantify transcriptional output. Cell proliferation and apoptosis assays enable phenotypic profiling in response to cytokines and candidate therapeutics. Researchers can leverage this model to validate ANKHD1’s role in signaling networks and to screen for compounds that modulate pathway activity. It supports applications in JAK-STAT signaling research, leukemia and cancer biology, drug target identification, and functional genomics. For further details, please contact Ascent Research.
